The evidence of pre-existing CD4+ T cell populations to influenza virus and their direct involvement in the in vivo elimination of virus-infected cells during primary and secondary infections have prompted Savic and colleagues to the development of an epitope-based universal influenza vaccine (60) (Table 1). The gene discussed is CD4; the disease is infection.